Gaëlle Vandermeulen

Suggest Changes
Learn More
BACKGROUND Nonviral gene therapy requires a high yield and a low cost production of eukaryotic expression vectors that meet defined criteria such as biosafety and quality of pharmaceutical grade. To(More)